Laboratory surveillance for SARS-CoV-2 in India
Priya Abraham(ICMR-National Institute of Virology), Naveen S Yadav(Indian Council of Medical Research), Varsha Potdar(ICMR-National Institute of Virology), Kiran Rade(World Health Organization - India), Sidhartha Giri(Indian Council of Medical Research), D. C. S. Reddy, Ira Praharaj(Indian Council of Medical Research), Naman K. Shah, Ajay Singh Dhama, Manoj Murhekar(National Institute of Epidemiology), Balram Bhargava(Indian Council of Medical Research), Suganya Barani(Institute of Public Health Bengaluru), Nivedita Gupta(National Center for Disease Control), Neeraj Aggarwal(ICMR-National Institute of Virology), V. Saravanakumar(National Institute of Epidemiology), K. B. Kurup, Raman R. Gangakhedkar(National Center for Disease Control), Jeromie Wesley Vivian Thangaraj(National Institute of Cancer Prevention and Research), P Manickam, Tarun Bhatnagar(Indian Council of Medical Research), Harpreet Singh
Cited by 81
Related Papers
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India
|Microorganisms|2021|658
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
|The Lancet|2021|361
Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India
|bioRxiv (Cold Spring Harbor Laboratory)|2021|268
Prevalence of SARS-CoV-2 infection in India
|The Indian Journal of Medical Research|2020|225